Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02384018 · ClinicalTrials.gov registry record · Phase 1
Mesenchymal Stem Cell and Islet Co-transplantation
A Phase 1 study, sponsored by Medical University of South Carolina.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT02384018 is a Phase 1 study that has completed, run by Medical University of South Carolina. The registered enrollment target is 3 participants.
The verdict
NCT02384018, a Phase 1 study, has completed, sponsored by Medical University of South Carolina.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to show safety and tolerability to our mesenchymal stromal cells (MSCs) product which will be autologous in nature, expanded using a non-xenogeneic, human component expansion media (pooled human platelet lysate) and delivered fresh. Subsequently, the investigators intend to test whether infusion of MSCs immediately after islet autograft can reduce onset of diabetes and improve glycemic control after total pancreatectomy and islet autotransplantation.
Interventions
- BIOLOGICAL autologous mesenchymal stromal cell
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2014-12 |
| Est. Completion | 2017-11-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02384018
The ClinicalTrials.gov registry entry for NCT02384018 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which autologous mesenchymal stromal cell is the first listed.
NCT02384018 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02384018 about?
NCT02384018 is a clinical study titled "Mesenchymal Stem Cell and Islet Co-transplantation". The purpose of this study is to show safety and tolerability to our mesenchymal stromal cells (MSCs) product which will be autologous in nature, expanded using a non-xenogeneic, human component expansion media (pooled human platelet lysate) and delivered fresh. Subsequently, the investigators intend...
What is the current status of trial NCT02384018?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2014-12. Estimated completion is 2017-11-21.
What interventions are being tested in trial NCT02384018?
The interventions under investigation include: autologous mesenchymal stromal cell (BIOLOGICAL).
Who is sponsoring clinical trial NCT02384018?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.